Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Otonomy Inc (NASDAQ: OTIC) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Otonomy Inc (NASDAQ: OTIC)  concerning whether a series of statements by Otonomy Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On August 30, 2017, the Company revealed that its Phase 3 clinical trial of OTIVIDEX in patients with Ménière's disease missed its primary endpoint. Additionally, Otonomy revealed an immediate suspension of all development activities for OTIVIDEX. The President and CEO of Otonomy, stated “We are greatly disappointed by these results, and surprised by both the higher placebo response and lower OTIVIDEX improvement than observed in our previous trials.”

Following this news, NASDAQ: OTIC declined, causing investors harm.

Based in San Diego, California, and founded in 2008 Otonomy Inc a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States.

If you purchased shares of Otonomy Inc (NASDAQ:OTIC) on or before August 30, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185